RAD51C and breast cancer: Furthermore, in BRIDGES, these spliceogenic variants account for 44.9% of all patients carrying a pathogenic/likely pathogenic variant (data not shown), indicating that a high proportion of RAD51C breast cancer risk-associated alleles displays splicing defects, as previously described for BRCA1 and BRCA2 [21].